This Dividend Giant Pfizer Could Turn a Boring Healthcare Allocation Into Serious Income

Pfizer is dealing with headwinds right now, but they aren't unusual headwinds in the pharmaceutical sector. The company is taking aggressive actions to get back on track and recently stated it plans to support its dividend.

The Motley Fool • 14 hours ago

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

In the latest China pharmaceutical industry collaboration pact with a global drug leader, Hangzhou Sciwind Biosciences said today it had reached an agreement with Pfizer China to team up on the commercialization of a new-generation weight management and diabetes treatment, in a deal worth up to $495 million for the Chinese company.

Forbes • 15 hours ago

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation based on results from the global Phase 3 BREAKWATER trial (NCT04607421). BRAFTOVI in combination with cetuximab and mFOLFOX6 was granted.

Business Wire • 9 hours ago

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

U.S. Food and Drug Administration Commissioner Marty Makary on Monday defended his agency's position and record on mRNA vaccines, days after it changed course and agreed to review a Moderna flu vaccine.

Reuters • Feb 23, 2026

Pfizer in diabetes drug deal with Sciwind Biosciences

Pfizer has entered an agreement to license Sciwind Biosciences' type 2 diabetes treatment ecnoglutide, with potential payments of up to $495 million if milestones are met, the Chinese drugmaker said on Tuesday.

Reuters • Feb 24, 2026

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Investment Research • Feb 23, 2026

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 a.m. EST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and we.

Business Wire • Feb 23, 2026

My 5 Favorite Dividend Stocks to Buy Right Now

It may be the right time for investors to start playing a little less offense and a little more defense. The best defensive names, however, are shares of businesses that continue to generate cash flow regardless of the economic environment.

The Motley Fool • Feb 22, 2026

Massive News: Pfizer's 6% Dividend Could Be Safer Than You Think

Pfizer (PFE 0.73%) offers a rare mix of scale, stability, and a 6% dividend yield that few large caps can match. With steady cash flow, modest valuation, and analyst upside, this defensive giant may be quietly positioning for a rebound.

The Motley Fool • Feb 21, 2026

Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash?

Pfizer has reached a transition point following declines of some of its biggest blockbusters. The pharma giant is paving the way to growth through new products and acquisitions.

The Motley Fool • Feb 20, 2026